Macro Factors Behind OptimizeRx's Weaker Than Expected Q2 Earnings, Lowers Annual Guidance

Macro Factors Behind OptimizeRx's Weaker Than Expected Q2 Earnings, Lowers Annual Guidance
  • OptimizeRx Corp OPRX shares are down over 25% after it cut FY22 sales guidance to $62-$68 million, representing Y/Y growth of 1% - 11%, respectively, and gross margins to be between 59% - 62%. 
  • Analysts expect the company to report FY22 sales of $81.44 million.
  • Earlier, the company expected FY22 sales of $80-$85 million and gross margins of 57% - 60%.
  • The company says that 2H 2022's outlook is driven by temporary life sciences industry challenges related to a slowdown in the number of new drug approvals, increased turnover rates at client companies, and longer sales cycles associated with larger deal sizes in the funnel.
  • OptimizeRx reported Q2 revenue of $13.98 million, up 3%, driven by new customer and program launches, missing the consensus of $16.87 million.
  • Gross margin increased to 64% from 59%, related to a more favorable channel partner and solution mix.
  • The company reported Q2 adjusted EPS of $0.04, missing the consensus of $0.09.
  • Price Action: OPRX shares are down 25.8% at $16.51 during the premarket session on the last check Wednesday.

Posted In: Briefspremarket tradingwhy it's movingEarningsNewsGuidanceHealth CareSmall CapMoversTrading IdeasGeneral